Raluca Verona

6.2k total citations · 2 hit papers
61 papers, 3.2k citations indexed

About

Raluca Verona is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Raluca Verona has authored 61 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 32 papers in Hematology and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Raluca Verona's work include Multiple Myeloma Research and Treatments (32 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and CAR-T cell therapy research (26 papers). Raluca Verona is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and CAR-T cell therapy research (26 papers). Raluca Verona collaborates with scholars based in United States, Netherlands and Spain. Raluca Verona's co-authors include Marisa S. Bartolomei, Mellissa R.W. Mann, Jacqueline A. Lees, Leisha D. Nolen, Jeffrey M. Trimarchi, Richard M. Schultz, Kenneth H. Moberg, Adam S. Doherty, Niels W.C.J. van de Donk and Catherine Rogers and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Raluca Verona

59 papers receiving 3.1k citations

Hit Papers

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antib... 2022 2026 2023 2024 2022 2024 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
    2022 350 citations Ajai Chari, Monique C. Minnema et al. profile →
  2. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
    2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Raluca Verona
Stefan Früehauf Germany
Norihiko Kawamata Japan
Jacalyn Rosenblatt United States
Blanca Scheijen Netherlands
Anupama Narla United States
Lisa A. Moreau United States
Irina V. Lagutina United States
Caryn Y. Ito Canada
Arjan Buijs Netherlands
Ronald Berenson United States
Stefan Früehauf Germany
Raluca Verona
Citations per year, relative to Raluca Verona Raluca Verona (= 1×) peers Stefan Früehauf

Countries citing papers authored by Raluca Verona

Since Specialization
Citations

This map shows the geographic impact of Raluca Verona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raluca Verona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raluca Verona more than expected).

Fields of papers citing papers by Raluca Verona

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raluca Verona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raluca Verona. The network helps show where Raluca Verona may publish in the future.

Co-authorship network of co-authors of Raluca Verona

This figure shows the co-authorship network connecting the top 25 collaborators of Raluca Verona. A scholar is included among the top collaborators of Raluca Verona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raluca Verona. Raluca Verona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Kristine A. Frerichs, et al.. (2024). T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma. Clinical Cancer Research. 30(14). 3006–3022. 25 indexed citations
2.
Rodríguez‐Otero, Paula, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, et al.. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. 14(1). 24–24. 51 indexed citations breakdown →
3.
Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900. 36 indexed citations
4.
Martin, Thomas G, María‐Victoria Mateos, Ajay K. Nooka, et al.. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 129(13). 2035–2046. 28 indexed citations
5.
Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S224–S224. 3 indexed citations
6.
7.
Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2022). Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Advances. 7(4). 644–648. 30 indexed citations
8.
Martens, Anne W. J., Renate de Boer, An Ngo‐Huang, et al.. (2022). Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications. 2(5). 330–341. 9 indexed citations
9.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. 5(8). 2196–2215. 117 indexed citations
10.
11.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Amy P. Wong, et al.. (2020). Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. Blood. 136(Supplement 1). 8–9. 7 indexed citations
12.
Thompson, Jeffrey C., Wei‐Ting Hwang, Christiana Davis, et al.. (2019). Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer. 139. 1–8. 93 indexed citations
13.
Wiehagen, Karla R., Natasha Girgis, Douglas H. Yamada, et al.. (2017). Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity. Cancer Immunology Research. 5(12). 1109–1121. 135 indexed citations
14.
Chornoguz, Olesya, Karen Leander, Fred M. Kaplan, et al.. (2017). TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1. The Journal of Immunology. 199(12). 4091–4102. 30 indexed citations
15.
Reese, Kimberly J., Shu Lin, Raluca Verona, Richard M. Schultz, & Marisa S. Bartolomei. (2007). Maintenance of Paternal Methylation and Repression of the Imprinted H19 Gene Requires MBD3. PLoS Genetics. 3(8). e137–e137. 65 indexed citations
16.
Thorvaldsen, Joanne L., Raluca Verona, & Marisa S. Bartolomei. (2006). X-tra! X-tra! News from the Mouse X Chromosome. Developmental Biology. 298(2). 344–353. 35 indexed citations
17.
Aslanian, Aaron, Phillip J. Iaquinta, Raluca Verona, & Jacqueline A. Lees. (2004). Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes & Development. 18(12). 1413–1422. 145 indexed citations
18.
Verona, Raluca & Marisa S. Bartolomei. (2004). Role of H19 3′ sequences in controlling H19 and Igf2 imprinting and expression. Genomics. 84(1). 59–68. 11 indexed citations
19.
Mann, Mellissa R.W., Young Gie Chung, Leisha D. Nolen, et al.. (2003). Disruption of Imprinted Gene Methylation and Expression in Cloned Preimplantation Stage Mouse Embryos1. Biology of Reproduction. 69(3). 902–914. 259 indexed citations
20.
Verona, Raluca, et al.. (1997). E2F Activity Is Regulated by Cell Cycle-Dependent Changes in Subcellular Localization. Molecular and Cellular Biology. 17(12). 7268–7282. 192 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Früehauf Breakdown of academic impact, for papers by Norihiko Kawamata Breakdown of academic impact, for papers by Jacalyn Rosenblatt Breakdown of academic impact, for papers by Blanca Scheijen Breakdown of academic impact, for papers by Anupama Narla Breakdown of academic impact, for papers by Lisa A. Moreau Breakdown of academic impact, for papers by Irina V. Lagutina Breakdown of academic impact, for papers by Caryn Y. Ito Breakdown of academic impact, for papers by Arjan Buijs Breakdown of academic impact, for papers by Ronald Berenson
Rankless by CCL
2026